González-Quintana Víctor, Palma-Berré Lizbeth, Campos-Parra Alma D, López-Urrutia Eduardo, Peralta-Zaragoza Oscar, Vazquez-Romo Rafael, Pérez-Plasencia Carlos
Cancer Genomics Laboratory, UBIMED, FES-Iztacala, UNAM, Los Reyes Iztacala, Tlalnepantla, México.
Cancer Genomics Laboratory, National Cancer Institute of Mexico, Tlalpan, México, DF, México.
Oncol Rep. 2016 Jan;35(1):3-12. doi: 10.3892/or.2015.4369. Epub 2015 Oct 30.
Cervical cancer (CC) is the third most diagnosed cancer among females worldwide and the fourth cause of cancer-related mortality. Prophylactic HPV vaccines and traditional pap-smear screening are undoubtedly capable of decreasing the incidence and mortality of CC. However, a large number of females succumb to the disease each year due to late diagnosis and resistance to conventional treatments. Thus, it is necessary to identify new molecular markers to predict the clinical outcome and to design powerful treatments. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are involved in the modulation of several cell pathways associated with progression from pre-malignant to invasive and metastatic disease, increasing tumor malignancy. The aim of this review was to summarize the recent data that describe the important role of miRNAS involved in CC in order to determine their potential as prognostic biomarkers and as therapy targets. Studies of >40 miRNAs with roles in cancer regulation were identified. We also identified 17 miRNAs associated with progression, 12 involved with clinical outcome and 7 that improved CC treatment response. The present review is expected to broaden understanding of the functional role and potential clinical uses of miRNAs in CC.
宫颈癌（CC）是全球女性中第三大最常被诊断出的癌症，也是癌症相关死亡的第四大原因。预防性人乳头瘤病毒（HPV）疫苗和传统的巴氏涂片筛查无疑能够降低宫颈癌的发病率和死亡率。然而，每年仍有大量女性因诊断延迟和对传统治疗产生耐药性而死于该病。因此，有必要识别新的分子标志物以预测临床结果并设计有效的治疗方法。微小RNA（miRNA）是一类小的非编码RNA，可调节基因表达，并参与调节与从癌前病变发展为浸润性和转移性疾病相关的多种细胞途径，从而增加肿瘤的恶性程度。本综述的目的是总结近期描述miRNA在宫颈癌中重要作用的数据，以确定它们作为预后生物标志物和治疗靶点的潜力。我们确定了40多种在癌症调控中起作用的miRNA的研究。我们还确定了17种与疾病进展相关的miRNA、12种与临床结果相关的miRNA以及7种可改善宫颈癌治疗反应的miRNA。本综述有望拓宽对miRNA在宫颈癌中的功能作用和潜在临床应用 的理解。
